AUS
NZ
UK
CA
USA
IND
Highlights:
Insulet Corporation (PODD), a leader in insulin delivery systems, has seen a 41.8% increase in its stock price over the past 52 weeks, outperforming the S&P 500 Index.
Despite strong performance in 2023, PODD's year-to-date (YTD) gain in 2024 is 22.8%, lagging behind the broader market’s 26.2% growth.
Following strong Q3 results, including revenue of $543.9 million and adjusted earnings per share (EPS) of $0.90, Insulet raised its full-year revenue growth forecast to 20%-21%.
Insulet Corporation (NASDAQ:PODD) , based in Acton, Massachusetts, is a global leader in developing insulin delivery systems for individuals with insulin-dependent diabetes. The company’s key products include the Omnipod Insulin Management System, with advanced solutions such as Omnipod 5, Omnipod DASH, and Omnipod GO. These devices are designed to provide discreet, user-friendly insulin management for patients.
Over the past 52 weeks, Insulet's shares have outperformed the broader market, rising 41.8%, compared to the S&P 500 Index's 32.1% increase. In 2024, however, the stock has gained 22.8%, trailing behind the S&P 500’s year-to-date growth of 26.2%. Despite this, the company has outpaced the Health Care Select Sector SPDR Fund (XLV), which has risen 11.5% over the past 52 weeks, and 7.2% on a YTD basis.
In November 2024, following the release of its Q3 earnings report, Insulet’s shares jumped 9.4%. The company posted quarterly revenue of $543.9 million and adjusted earnings per share (EPS) of $0.90, both exceeding analyst expectations. This performance led Insulet to raise its full-year revenue growth forecast to 20%-21%, with Omnipod revenue growth projected to increase by 21%-22%. The approval of Omnipod 5 for use in type 2 diabetes, along with expectations for stronger customer additions in the latter half of the year, further bolstered investor confidence.
For the current fiscal year, Insulet is anticipated to report an EPS of $3.22, reflecting a 17.1% year-over-year growth. The company's earnings history has been somewhat mixed, with three earnings beats and one miss in the past four quarters. Of the 21 analysts covering the stock, the consensus is a "Strong Buy," supported by 17 "Strong Buy" ratings, one "Moderate Buy," and three "Holds."
